TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07322094: CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

Sponsor: TORL Biotherapeutics, LLC · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,295,910

Rescue Site Savings

+$863,940

Unlock Full NCT07322094 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07322094 Rescue Dossier →